# Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-d72b7023
Ticker: GLUE
Company: Monte Rosa Therapeutics
Source: Monte Rosa Therapeutics
Published: 2026-09-01 11:00 EST
## Summary

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced ...

## Article Body
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:

Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 10, 2026, at 12:45 p.m. ET

Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY) – September 14, 2026

A webcast of the fireside chat will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com , and archived versions will be made available for 30 days following the presentations.

About Monte Rosa Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit www.monterosatx.com .

Investors Andrew Funderburk ir@monterosatx.com

Media Cory Tromblee, Scient PR media@monterosatx.com
## Recent Company News
- 2026-09-02 20:01 EST — [Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GLUE/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-0aff4d5a) — Source: Monte Rosa Therapeutics
- 2026-09-01 11:00 EST — [Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-d72b7023) — Source: Monte Rosa Therapeutics
- 2026-08-24 11:00 EST — [Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer](https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-announces-first-patient-dosed-in-modefire-1-a-phase-2-st-6ba828c9) — Source: Monte Rosa Therapeutics
- 2026-08-06 11:00 EST — [Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-announces-second-quarter-2026-financial-results-and-busi-1240d177) — Source: Monte Rosa Therapeutics
- 2026-07-02 20:01 EST — [Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GLUE/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bc49cd8f) — Source: Monte Rosa Therapeutics
## Related News
- 2026-09-04 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e23953dd)
- 2026-09-04 20:05 EST — RPID — [Rapid Micro Biosystems to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-upcoming-investor-conferences-91a8800f)
- 2026-09-04 20:05 EST — LIXT — [NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS](https://biopharmsignal.com/news/LIXT/nomad-power-solutions-announces-adjournment-of-special-meeting-of-stockholders-74cd9e2e)
- 2026-09-04 20:05 EST — AVTX — [Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-lis-cc7baaf2)
- 2026-09-04 20:05 EST — NTLA — [Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-250d5dd9)